Last updated: 2026-09-04 13:34:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Gelteq Limited (GELS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0.78, with a market capitalisation of $7.50M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.39 to $2.02. This page covers its latest market performance, valuation, price trends and company information.
$7.50M | |
$0.81 | |
$5.50 | |
$0.39 | |
$0.89 | |
116.72K | |
-- | |
-- | |
$2.02 | |
$0.39 | |
-- | |
-- |
Gelteq Limited (GELS) is currently trading at $0.78 as of 2026-09-04 13:33:00, down 12.34% ($0.11) from the previous close of $0.89
During today's regular trading session, GELS has traded between $0.39 and $5.50, with a trading volume of 116.72K shares. The current price is near the lower end of today's range.
Over the past seven days, Gelteq Limited (GELS) moved from $0.55 to $0.78, representing a gain of 42.65% ($0.23).
The stock traded between $0.78 and $0.81 during the period. The latest price is near the lower end of the 7-day range, indicating strong upward.
The average daily volume was 20.26 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 24.2%
GELS is currently trading at $0.78, placing it 24.2% of the way from its 52-week low of $0.39 to its 52-week high of $2.02. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Gelteq Limited (GELS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.